resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-
associated protein 1 and provokes high levels of cross-resistance to glucocorticoids.
Arthritis Rheum 2006;54:557–568.
Ogihara T, Kamiya M, Ozawa M, Fujita T, Yamamoto A, Yamashita S, Ohnishi S,
Isomura Y. What kinds of substrates show P-glycoprotein-dependent intestinal
absorption? Comparison of verapamil with vinblastine. Drug Metab Pharmacokinet
2006;21:238–244.
Ohmori S, Kuriya S, Uesugi T, Horie T, Sagami F, Mikami T, Kawaguchi A, Rikihisa
T, Kanakubo Y. Decrease in the specific forms of cytochrome P-450 in liver
microsomes of a mutant strain of rat with hyperbilirubinuria. Res Commun Chem
Pathol Pharmacol 1991;72:243–253.
Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, Komano T,
Hori R. Digoxin–cyclosporin A interaction: modulation of the multidrug transporter
P-glycoprotein in the kidney. J Pharmacol Exp Ther 1993;266:1614–1619.
Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B. Functional
characterization of the human multidrug transporter, ABCG2, expressed in insect
cells. Biochem Biophys Res Commun 2001;285:111–117.
Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis,
and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation
of substrate specificity by a point mutation. J Biol Chem 2002;277:47980–47990.
Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P-
glycoprotein mediate the interaction between an oral erythromycin breath test and
rifampin. Clin Pharmacol Ther (St. Louis, MO, United States) 2002;72:524–535.
Paul AJ, Tranquilli WJ, Seward RL, Todd KS, Jr, DiPietro JA. Clinical observations in
collies given ivermectin orally. Am J Vet Res 1987;48:684–685.
Pedersen KE, Christiansen BD, Klitgaard NA, Nielsen-Kudsk F. Effect of quinidine on
digoxin bioavailability. Eur J Clin Pharmacol 1983;24:41–47.
Perloff MD, Von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John’s wort:
anin vitroanalysis of P-glycoprotein induction due to extended exposure. Br J
Pharmacol 2001;134:1601–1608.
Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brueck P,
Binckebanck A, Schleyer E, Goekbuget N, Wolff T, Luebbert M, Leimer L,
Gschaidmeier H, Hoelzer D, Ottmann OG. Risk and prognosis of central nervous
system leukemia in patients with Philadelphia chromosome-positive acute leukemias
treated with imatinib mesylate. Clin Cancer Res 2003;9:4674–4681.
Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D.In vivoRNA interference-
mediated ablation of MDR1 P-Glycoprotein. Clin Cancer Res 2005;11:4487–4494.
Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations
and St John’s wort. Lancet 2000;355:547–548.
Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic
supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:
234–238.
Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh
CS. Rational use ofin vitroP-glycoprotein assays in drug discovery. J Pharmacol Exp
Ther 2001;299:620–628, Promega. Available at http://www.promega.com/tbs/tb341/
tb341.pdf.
196 DRUG TRANSPORTERS IN DRUG DISPOSITION, DRUG INTERACTIONS